Indeed, the efficiency of first‐generation rAAV vectors in supplementing the RPE65 gene function resulted in market authorization of voretigene neparvovec for the treatment of RPE65‐linked retinal dystrophies, first in the United States and the following year in Europe (Keeler & Flotte, 2019). The gene discussed is RPE65; the disease is Retinal dystrophy.